Johnson & Johnson has been fighting thousands of lawsuits over its now-discontinued talc products for 16 years. A pending ...

Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Johnson & Johnson MedTech announced today that the FDA cleared its Monarch Quest technology for robotic-assisted bronchoscopy ...

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15 th to review first-quarter results.

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), ...